New dihydropyrimidin-2(1H)-one based Hsp90 C-terminal inhibitors

The inhibition of the C-terminal domain of heat shock protein 90 (Hsp90) is emerging as a novel strategy for cancer therapy, therefore the identification of a new class of C-terminal inhibitors is strongly required, also in consideration that to date only nature-inspired molecules have been largely expanded. Our recent discovery of potent antiproliferative dihydropyrimidone based C-terminal Hsp90 inhibitor (1, IC50 = 50.8 ± 0.2 μM and 20.8 ± 0.3 μM in A375 and Jurkat cell lines, respectively) drove us to further explore this very promising pharmacophoric core. In this study, we identified a new set of DHPM-derivatives that exhibited antiproliferative activity against two cancer lines by their modulation of Hsp90 C-terminus without inducing the undesired heat shock response. Our results strongly outline the high sensitivity of the Biginelli scaffold to structural decorations allowing us to point out also that small variations can deeply influence biological activity.

[1]  R. Dobrowsky,et al.  Development of Noviomimetics as C-Terminal Hsp90 Inhibitors. , 2016, ACS medicinal chemistry letters.

[2]  C. Hudis,et al.  A multicenter trial evaluating retaspimycin HCL (IPI-504) plus trastuzumab in patients with advanced or metastatic HER2-positive breast cancer , 2013, Breast Cancer Research and Treatment.

[3]  N. Rosen,et al.  17AAG: low target binding affinity and potent cell activity--finding an explanation. , 2003, Molecular cancer therapeutics.

[4]  David Siegel,et al.  Formation of 17-allylamino-demethoxygeldanamycin (17-AAG) hydroquinone by NAD(P)H:quinone oxidoreductase 1: role of 17-AAG hydroquinone in heat shock protein 90 inhibition. , 2005, Cancer research.

[5]  B. Blagg,et al.  Natural Product Inspired N‐Terminal Hsp90 Inhibitors: From Bench to Bedside? , 2016, Medicinal research reviews.

[6]  S. Larson,et al.  Affinity-based proteomics reveal cancer-specific networks coordinated by Hsp90. , 2011, Nature chemical biology.

[7]  G. Bifulco,et al.  9H-Purine Scaffold Reveals Induced-Fit Pocket Plasticity of the BRD9 Bromodomain , 2015, Journal of medicinal chemistry.

[8]  I. Benjamin,et al.  Induction of a heat shock factor 1-dependent stress response alters the cytotoxic activity of hsp90-binding agents. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[9]  Y. Miyata,et al.  The Therapeutic Target Hsp90 and Cancer Hallmarks , 2012 .

[10]  C. Kappe,et al.  Automated library generation using sequential microwave-assisted chemistry. Application toward the Biginelli multicomponent condensation. , 2001, Journal of combinatorial chemistry.

[11]  B. Blagg,et al.  Synthesis and biological evaluation of coumarin replacements of novobiocin as Hsp90 inhibitors. , 2014, Bioorganic & medicinal chemistry.

[12]  T. Haystead,et al.  Hsp90, an unlikely ally in the war on cancer , 2013, The FEBS journal.

[13]  Yao Wang,et al.  Blocking the heat shock response and depleting HSF-1 levels through heat shock protein 90 (hsp90) inhibition: a significant advance on current hsp90 chemotherapies , 2015 .

[14]  C. Garrido,et al.  Targeting heat shock proteins in cancer. , 2013, Cancer letters.

[15]  Yao Wang,et al.  Chemically accessible hsp90 inhibitor that does not induce a heat shock response. , 2014, ACS medicinal chemistry letters.

[16]  Giorgio Colombo,et al.  Exploiting Conformational Dynamics in Drug Discovery: Design of C-Terminal Inhibitors of Hsp90 with Improved Activities , 2014, J. Chem. Inf. Model..

[17]  Yao Wang,et al.  C-terminal heat shock protein 90 modulators produce desirable oncogenic properties. , 2015, Organic & biomolecular chemistry.

[18]  B. Blagg,et al.  Synthesis and evaluation of coumermycin A1 analogues that inhibit the Hsp90 protein folding machinery. , 2006, Organic letters.

[19]  J. Hall,et al.  Triazole Containing Novobiocin and Biphenyl Amides as Hsp90 C-Terminal Inhibitors. , 2014, MedChemComm.

[20]  F. Zunino,et al.  The enhancement of antiproliferative and proapoptotic activity of HDAC inhibitors by curcumin is mediated by Hsp90 inhibition , 2010, Cellular and Molecular Life Sciences.

[21]  C. Kappe.  Biologically active dihydropyrimidones of the Biginelli-type--a literature survey. , 2000, European journal of medicinal chemistry.

[22]  Woody Sherman,et al.  Use of an Induced Fit Receptor Structure in Virtual Screening , 2006, Chemical biology & drug design.

[23]  B. Blagg,et al.  Synthesis and Biological Evaluation of Novobiocin Core Analogues as Hsp90 Inhibitors. , 2016, Chemistry.

[24]  L. Neckers,et al.  The Heat Shock Protein 90 Antagonist Novobiocin Interacts with a Previously Unrecognized ATP-binding Domain in the Carboxyl Terminus of the Chaperone* , 2000, The Journal of Biological Chemistry.

[25]  D. Hanahan,et al.  Hallmarks of Cancer: The Next Generation , 2011, Cell.

[26]  Ta-Wei Lin,et al.  The Hexameric Structures of Human Heat Shock Protein 90 , 2011, PloS one.

[27]  Theodora Stivarou,et al.  Targeting highly expressed extracellular HSP90 in breast cancer stem cells inhibits tumor growth in vitro and in vivo , 2016, Cancer biology & therapy.

[28]  R. Friesner,et al.  Novel procedure for modeling ligand/receptor induced fit effects. , 2006, Journal of medicinal chemistry.

[29]  G. Bifulco,et al.  Structural Insights for the Optimization of Dihydropyrimidin-2(1H)-one Based mPGES-1 Inhibitors. , 2015, ACS medicinal chemistry letters.

[30]  S. McAlpine,et al.  A heat shock protein 90 inhibitor that modulates the immunophilins and regulates hormone receptors without inducing the heat shock response. , 2014, Bioorganic & medicinal chemistry letters.

[31]  Joshua A. Kritzer,et al.  Potential C-terminal-domain inhibitors of heat shock protein 90 derived from a C-terminal peptide helix. , 2014, Bioorganic & medicinal chemistry.

[32]  L. Pearl,et al.  Crystal structure of an Hsp90–nucleotide–p23/Sba1 closed chaperone complex , 2006, Nature.

[33]  A. Olshen,et al.  Inhibition of heat shock protein 90 function down-regulates Akt kinase and sensitizes tumors to Taxol. , 2003, Cancer research.

[34]  M. Cooper.  Label-free screening of bio-molecular interactions , 2003, Analytical and bioanalytical chemistry.

[35]  B. Blagg,et al.  Novobiocin and additional inhibitors of the Hsp90 C-terminal nucleotide-binding pocket. , 2008, Current medicinal chemistry.

[36]  Chung-Mao Pan,et al.  Design and synthesis of Hsp90 inhibitors: exploring the SAR of Sansalvamide A derivatives. , 2010, Bioorganic & medicinal chemistry.

[37]  G. Giaccone,et al.  Integration of Gene Dosage and Gene Expression in Non-Small Cell Lung Cancer, Identification of HSP90 as Potential Target , 2008, PloS one.

[38]  E. Holler,et al.  Heat-shock protein expression in leukemia , 2011, Tumor Biology.

[39]  M. Lerch,et al.  Heat shock protein 70 increases tumorigenicity and inhibits apoptosis in pancreatic adenocarcinoma. , 2007, Cancer research.

[40]  G. Bifulco,et al.  Targeting the Hsp90 C-terminal domain by the chemically accessible dihydropyrimidinone scaffold. , 2015, Chemical communications.

[41]  G. Colombo,et al.  Design, synthesis and biological evaluation of biphenylamide derivatives as Hsp90 C-terminal inhibitors. , 2015, European journal of medicinal chemistry.

[42]  J. Hall,et al.  Alternative approaches to Hsp90 modulation for the treatment of cancer. , 2014, Future medicinal chemistry.

[43]  A. Leone,et al.  Identification of the Plant Compound Geraniin as a Novel Hsp90 Inhibitor , 2013, PloS one.

[44]  C. Erlichman,et al.  Up-regulation of heat shock protein 27 induces resistance to 17-allylamino-demethoxygeldanamycin through a glutathione-mediated mechanism. , 2006, Cancer research.

[45]  B. Blagg,et al.  Novologues containing a benzamide side chain manifest anti-proliferative activity against two breast cancer cell lines. , 2014, Bioorganic & medicinal chemistry letters.

[46]  R. Hales,et al.  Novel Hsp90 inhibitor NVP-AUY922 radiosensitizes prostate cancer cells , 2012, Cancer biology & therapy.

[47]  L. Fritz,et al.  A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors , 2003, Nature.

[48]  Huiping Zhao,et al.  Cytotoxic sugar analogues of an optimized novobiocin scaffold , 2010 .

[49]  J. Kremsner,et al.  5-aroyl-3,4-dihydropyrimidin-2-one library generation via automated sequential and parallel microwave-assisted synthesis techniques. , 2007, Journal of combinatorial chemistry.

[50]  F. Tommasi,et al.  Effect of some light rare earth elements on seed germination, seedling growth and antioxidant metabolism in Triticum durum. , 2009, Chemosphere.

[51]  Woody Sherman,et al.  Protein and ligand preparation: parameters, protocols, and influence on virtual screening enrichments , 2013, Journal of Computer-Aided Molecular Design.

[52]  G. Bifulco,et al.  Molecular decodification of gymnemic acids from Gymnema sylvestre. Discovery of a new class of liver X receptor antagonists , 2015, Steroids.

[53]  Paul Workman,et al.  Hsp90 Molecular Chaperone Inhibitors: Are We There Yet? , 2012, Clinical Cancer Research.

[54]  L. Schwartz,et al.  A phase II trial of 17-(Allylamino)-17-demethoxygeldanamycin in patients with papillary and clear cell renal cell carcinoma , 2006, Investigational New Drugs.

[55]  S. Lindquist,et al.  HSP90 and the chaperoning of cancer , 2005, Nature Reviews Cancer.

[56]  J. Larkin,et al.  A Phase II trial of 17-allylamino, 17-demethoxygeldanamycin (17-AAG, tanespimycin) in patients with metastatic melanoma , 2012, Investigational New Drugs.

[57]  G. Bifulco,et al.  A chemical-biological study reveals C9-type iridoids as novel heat shock protein 90 (Hsp90) inhibitors. , 2013, Journal of medicinal chemistry.

[58]  G. Bifulco,et al.  Natural Iminosugar (+)-Lentiginosine Inhibits ATPase and Chaperone Activity of Hsp90 , 2012, PloS one.

[59]  Xu Zhang,et al.  HSP27, 70 and 90, anti-apoptotic proteins, in clinical cancer therapy (Review). , 2014, International journal of oncology.